Marinus Pharmaceuticals Retains The Chase Group for Chief Medical Officer
Marinus Pharmaceuticals selected The Chase Group when they began their search for a new Chief Medical Officer. The Chase Group has had an on-going relationship with Marinus and because of the success with previous recruitments, the company put their trust in the team at TCG who has quickly secured a strong candidate slate for Christopher Cashman, Chairman and CEO, to make his final selection.
Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, an extensive safety database, and convenient dosing to improve the lives of patients suffering from drug-resistant seizures and neuropsychiatric disorders.
